AMENDMENTS TO THE CLAIMS

1-26. (Canceled)

- 27. (New) A pharmaceutical composition consisting essentially of an association of granulocyte colony stimulating factor (GCSF) and placental growth factor (PIGF) as the active ingredient, in combination with suitable excipients and/or adjuvants, wherein said association is able to mobilize peripheral blood progenitor cells (PBPCs), thereby increasing the number of circulating white blood cells, circulating colony forming blood cells or of circulating long term colony initiating blood cells.
- 28. (New) The pharmaceutical composition according to claim 27 containing recombinant hGCSF and recombinant hPIGF.
- 29. (New) The pharmaceutical composition according to claim 27 formulated for parenteral administration.
- 30. (New) A method for increasing the number of circulating white blood cells, circulating colony forming blood cells or of circulating long term colony initiating blood cells, comprising the sole step of administering either separately or simultaneously to a patient in need of such a treatment an effective amount of both granulocyte colony stimulating factor (GCSF) and placental growth factor (PIGF).
- 31. (New) The method according to claim 30, wherein the patient subjected to said treatment has undergone a procedure selected from the group consisting of: tumor chemo-radio therapy, autologous stem cells transplantation, allogeneic stem cells transplantation or said patient was treated by myelosuppressive chemo-therapy.
- 32. (New) The method according to claim 30, wherein said granulocyte colony stimulating factor (GCSF) and placental growth factor (PIGF) are administered separately or simultaneously by parenteral route.

- 33. (New) The method according to claim 30 comprising the sole step of administering either simultaneously or separately from 10 to 150 μg/kg of said granulocyte colony stimulating factor (GCSF) and from 10 to 300 μg/kg of said placental growth factor (PIGF).
- 34. (New) The method according to claim 30 comprising the sole step of administering simultaneously said granulocyte colony stimulating factor (GCSF) and said placental growth factor (PIGF).
- 35. (New) The method according to claim 34 comprising the sole step of administering a pharmaceutical composition consisting essentially of: an association of granulocyte colony stimulating factor (GCSF) and placental growth factor (PIGF) as the active ingredient, in combination with suitable excipients and/or adjuvants.
- 36. (New) The method according to claim 30, wherein said colony stimulating factor (GCSF) and placental growth factor (PIGF) are administered either sequentially or separately at intervals.